1. CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer
- Author
-
Walls, GM, Oughton, JB, Chalmers, AJ, Brown, S, Collinson, F, Forster, MD, Franks, KN, Gilbert, A, Hanna, GG, Hannaway, N, Harrow, S, Hinsley, S, Murden, G, Phillip, R, Anderson, RJ, Salem, A, Sebag-Montefoire, D, Shaw, P, Twelves, CJ, Walker, K, Young, RJ, Faivre-Finn, C, and Greystoke, A
- Abstract
Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for ‘gold standard’ treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding. Abbreviations ATM: Ataxia telangiectasia mutated ATR: Ataxia telangiectasia and Rad3 related cfDNA: Cell-free DNA CRT: Chemoradiotherapy CT: Computed tomography CTCAE: Common terminology criteria for adverse events CTRad: Clinical and Translational Radiotherapy Research Working Group DDRi: DNA damage response inhibitor DLT: Dose limiting toxicity DNA: Deoxyribonucleic acid DNA-PK: DNA-dependent protein kinase ECOG: Eastern Cooperative Oncology Group EORTC: European Organisation for Research and Treatment of Cancer ICRU: International Commission on Radiation Units and Measurements IMPs: Investigational medicinal products LA: Locally advanced MRC: Medical Research Council NCRI: National Cancer Research Institute NSCLC: Non-small cell lung cancer PARP: Poly (ADP-ribose) polymerase PET: Positron emission tomography PFS: Progression free survival PROMs: Patient-reported outcome measures RECIST: Response evaluation criteria in solid tumours RP2D: Recommended phase II dose RT: Radiotherapy SACT: Systemic anti-cancer therapy SRC: Safety review committee TiTE-CRM: Time to event continual reassessment method TNM: Tumour node metastasis
- Published
- 2020